annual CFF:
$1.19B+$1.10B(+1170.30%)Summary
- As of today (May 29, 2025), RNA annual cash flow from financing activities is $1.19 billion, with the most recent change of +$1.10 billion (+1170.30%) on December 31, 2024.
- During the last 3 years, RNA annual CFF has risen by +$1.02 billion (+576.26%).
- RNA annual CFF is now at all-time high.
Performance
RNA Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$1.94M-$11.79M(-85.89%)Summary
- As of today (May 29, 2025), RNA quarterly cash flow from financing activities is $1.94 million, with the most recent change of -$11.79 million (-85.89%) on March 31, 2025.
- Over the past year, RNA quarterly CFF has dropped by -$387.51 million (-99.50%).
- RNA quarterly CFF is now -99.57% below its all-time high of $446.72 million, reached on June 30, 2024.
Performance
RNA quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$804.85M-$387.51M(-32.50%)Summary
- As of today (May 29, 2025), RNA TTM cash flow from financing activities is $804.85 million, with the most recent change of -$387.51 million (-32.50%) on March 31, 2025.
- Over the past year, RNA TTM CFF has increased by +$344.50 million (+74.83%).
- RNA TTM CFF is now -33.51% below its all-time high of $1.21 billion, reached on September 30, 2024.
Performance
RNA TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
RNA Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +1170.3% | -99.5% | +74.8% |
| 3 y3 years | +576.3% | -92.0% | +301.6% |
| 5 y5 years | +1236.2% | +46.4% | +828.0% |
RNA Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +1170.3% | -99.6% | +4742.5% | -33.5% | +757.5% |
| 5 y | 5-year | at high | +1236.2% | -99.6% | +243.9% | -33.5% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -99.6% | +243.9% | -33.5% | >+9999.0% |
RNA Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $1.94M(-85.9%) | $804.85M(-32.5%) |
| Dec 2024 | $1.19B(+1170.3%) | $13.72M(-96.0%) | $1.19B(-1.5%) |
| Sep 2024 | - | $342.46M(-23.3%) | $1.21B(+39.4%) |
| Jun 2024 | - | $446.72M(+14.7%) | $868.10M(+88.6%) |
| Mar 2024 | - | $389.44M(+1121.2%) | $460.35M(+390.4%) |
| Dec 2023 | $93.86M(-72.9%) | $31.89M(>+9900.0%) | $93.86M(-69.3%) |
| Sep 2023 | - | $40.00K(-99.9%) | $305.63M(-11.5%) |
| Jun 2023 | - | $38.97M(+69.7%) | $345.21M(+0.1%) |
| Mar 2023 | - | $22.96M(-90.6%) | $345.02M(-0.3%) |
| Dec 2022 | $346.17M(+96.3%) | $243.65M(+515.0%) | $346.17M(+180.9%) |
| Sep 2022 | - | $39.62M(+2.2%) | $123.23M(-48.4%) |
| Jun 2022 | - | $38.78M(+60.8%) | $238.78M(+19.1%) |
| Mar 2022 | - | $24.11M(+16.4%) | $200.41M(+13.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $176.32M(-35.2%) | $20.71M(-86.7%) | $176.32M(+13.0%) |
| Sep 2021 | - | $155.17M(>+9900.0%) | $156.05M(<-9900.0%) |
| Jun 2021 | - | $413.00K(+2329.4%) | -$466.00K(-100.2%) |
| Mar 2021 | - | $17.00K(-96.2%) | $270.73M(-0.5%) |
| Dec 2020 | $272.04M(+204.9%) | $450.00K(-133.4%) | $272.04M(-20.8%) |
| Sep 2020 | - | -$1.35M(-100.5%) | $343.41M(-0.2%) |
| Jun 2020 | - | $271.61M(>+9900.0%) | $344.05M(+296.7%) |
| Mar 2020 | - | $1.32M(-98.2%) | $86.73M(-2.8%) |
| Dec 2019 | $89.23M(+1634.7%) | $71.82M(<-9900.0%) | $89.23M(+412.6%) |
| Sep 2019 | - | -$712.00K(-105.0%) | $17.41M(-3.9%) |
| Jun 2019 | - | $14.30M(+274.1%) | $18.12M(+374.1%) |
| Mar 2019 | - | $3.82M | $3.82M |
| Dec 2018 | $5.14M | - | - |
FAQ
- What is Avidity Biosciences annual cash flow from financing activities?
- What is the all time high annual CFF for Avidity Biosciences?
- What is Avidity Biosciences annual CFF year-on-year change?
- What is Avidity Biosciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Avidity Biosciences?
- What is Avidity Biosciences quarterly CFF year-on-year change?
- What is Avidity Biosciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Avidity Biosciences?
- What is Avidity Biosciences TTM CFF year-on-year change?
What is Avidity Biosciences annual cash flow from financing activities?
The current annual CFF of RNA is $1.19B
What is the all time high annual CFF for Avidity Biosciences?
Avidity Biosciences all-time high annual cash flow from financing activities is $1.19B
What is Avidity Biosciences annual CFF year-on-year change?
Over the past year, RNA annual cash flow from financing activities has changed by +$1.10B (+1170.30%)
What is Avidity Biosciences quarterly cash flow from financing activities?
The current quarterly CFF of RNA is $1.94M
What is the all time high quarterly CFF for Avidity Biosciences?
Avidity Biosciences all-time high quarterly cash flow from financing activities is $446.72M
What is Avidity Biosciences quarterly CFF year-on-year change?
Over the past year, RNA quarterly cash flow from financing activities has changed by -$387.51M (-99.50%)
What is Avidity Biosciences TTM cash flow from financing activities?
The current TTM CFF of RNA is $804.85M
What is the all time high TTM CFF for Avidity Biosciences?
Avidity Biosciences all-time high TTM cash flow from financing activities is $1.21B
What is Avidity Biosciences TTM CFF year-on-year change?
Over the past year, RNA TTM cash flow from financing activities has changed by +$344.50M (+74.83%)